Axogen Inc (NASDAQ:AXGN) Shareholder Next Century Growth Investors Llc Trimmed Position as Price Rose by $11.31 Million

May 17, 2018 - By Arnold Ferreira

AxoGen, Inc. (NASDAQ:AXGN) Corporate Logo

Next Century Growth Investors Llc decreased its stake by 47.07% in Axogen Inc (NASDAQ:AXGN), according to 2018Q1 Securities and Exchange filling. By selling 314,239 shares Next Century Growth Investors Llc made the stock Popped Up with 43.24%. The institutional investor is holding 353,403 shares, compared to the 667,642 from the previous quarter. And the reported value of the health care company is $12.90M for the 2018Q1. For a total of shares it increased its holding in by shares in the quarter, and has risen its stake in .

Next Century Growth Investors Llc is a Minnesota-based institutional investor with more than $3.86 billion AUM in March, 2014. Taken from Next Century Growth Investors latest Adv, the fund reported to have 10 full and part-time employees. Among which 6 performing investment advisory and research functions. The institutional investor had between 26-100 clients.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

A total of 7 analysts rate AxoGen (NASDAQ:AXGN) as follows: 7 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:AXGN) has 11 ratings reports on May 17, 2018 according to StockzIntelligence. The stock rating was maintained by Lake Street with “Buy” on Friday, March 2. In Tuesday, November 21 report Wedbush maintained the stock with “Buy” rating. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Monday, January 8. On Tuesday, November 21 the rating was maintained by Leerink Swann with “Outperform”. On Thursday, March 1 JMP Securities maintained AxoGen, Inc. (NASDAQ:AXGN) with “Market Outperform” rating. On Tuesday, May 1 Cantor Fitzgerald maintained AxoGen, Inc. (NASDAQ:AXGN) rating. Cantor Fitzgerald has “Overweight” rating and $45 target. On Wednesday, February 28 the stock of AxoGen, Inc. (NASDAQ:AXGN) has “Buy” rating given by Cantor Fitzgerald. On Tuesday, May 1 the rating was maintained by JMP Securities with “Market Outperform”.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries.The company has $1.66 billion market cap. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.Last it reported negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

AxoGen, Inc. (NASDAQ:AXGN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: